5 Most Undervalued Foreign Stocks to Buy Now

2. Novo Nordisk A/S (NYSE:NVO)

Forward Price to Earnings Ratio: 12.78

Number of Hedge Fund Holders: 55

Novo Nordisk A/S (NYSE:NVO) is one of the Most Undervalued Foreign Stocks to Buy Now. On May 6, Reuters reported that Novo Nordisk A/S (NYSE:NVO) topped first-quarter profit forecasts and also raised the full-year outlook slightly.

The results were driven by the company’s new Wegovy weight-loss pill, which was launched in the US in January. During the quarter the sales hit 2.26 billion Danish crowns, nearly double the analysts expectations. Moreover, the total prescriptions also topped the 2 million mark since its launch. The company calls this the strongest GLP-1 launch by volume in US history.

The adjusted operating profit for the quarter came in at 32.86 billion Danish crowns, and topped the expectation of 28.74 billion. Moreover, the group sales came in at 70.06 billion Danish, above the 69.07 billion ​expected by analysts. Looking ahead, Novo plans to expand the Wegovy pill beyond the US in the second half of 2026, with regulatory submissions already filed in Europe. The company forecasts full-year adjusted sales and operating profit to decline by 4% to 12%, better than the previously expected 5% to 13% decline.

Novo Nordisk (NYSE:NVO) is a drug manufacturer for global pharmaceutical products that operates through two segments: Obesity & Diabetes Care and Rare Disease. The company was founded in 1923 and is headquartered in Denmark.